How We Approach Suppressive Antibiotic Therapy Following Debridement, Antibiotics, and Implant Retention for Prosthetic Joint Infection

Clin Infect Dis. 2024 Jan 25;78(1):188-198. doi: 10.1093/cid/ciad484.

Abstract

The optimal treatment of prosthetic joint infection (PJI) remains uncertain. Patients undergoing debridement, antibiotics, and implant retention (DAIR) receive extended antimicrobial treatment, and some experts leave patients at perceived highest risk of relapse on suppressive antibiotic therapy (SAT). In this narrative review, we synthesize the literature concerning the role of SAT to prevent treatment failure following DAIR, attempting to answer 3 key questions: (1) What factors identify patients at highest risk for treatment failure after DAIR (ie, patients with the greatest potential to benefit from SAT), (2) Does SAT reduce the rate of treatment failure after DAIR, and (3) What are the rates of treatment failure and adverse events necessitating treatment discontinuation in patients receiving SAT? We conclude by proposing risk-benefit stratification criteria to guide use of SAT after DAIR for PJI, informed by the limited available literature.

Keywords: DAIR; PJI; antibiotic suppression; prosthetic joint infection; suppressive antibiotic therapy.

Publication types

  • Review

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Arthritis, Infectious* / drug therapy
  • Debridement
  • Humans
  • Prosthesis-Related Infections* / drug therapy
  • Prosthesis-Related Infections* / surgery
  • Retrospective Studies
  • Treatment Failure
  • Treatment Outcome

Substances

  • Anti-Bacterial Agents